German biotechnology firm CureVac raises $213.3 million Initial Public Offering on Nasdaq

German biotechnology firm CureVac raises $213.3 million Initial Public Offering on Nasdaq

German CureVac BV stock market debut of a company developing a potential vaccine to combat the coronavirus. The German biotechnology firm, backed by Microsoft Corp […]

Read More